Seasonal influenza poses serious problems for global public health, being a significant contributor to morbidity and mortality. In England, there has been a long-standing national vaccination programme, with vaccination of at-risk groups and children offering partial protection against infection. Transmission models have been a fundamental component of analysis, informing the efficient use of limited resources. However, these models generally treat each season and each strain circulating within that season in isolation. Here, we amalgamate multiple data sources to calibrate a susceptible-latent-infected-recovered type transmission model for seasonal influenza, incorporating the four main strains and mechanisms linking prior season epidemiological outcomes to immunity at the beginning of the following season. Data pertaining to nine influenza seasons, starting with the 2009/10 season, informed our estimates for epidemiological processes, virological sample positivity, vaccine uptake and efficacy attributes, and general practitioner influenza-like-illness consultations as reported by the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC). We performed parameter inference via approximate Bayesian computation to assess strain transmissibility, dependence of present season influenza immunity on prior protection, and variability in the influenza case ascertainment across seasons. This produced reasonable agreement between model and data on the annual strain composition. Parameter fits indicated that the propagation of immunity from one season to the next is weaker if vaccine derived, compared to natural immunity from infection. Projecting the dynamics forward in time suggests that while historic immunity plays an important role in determining annual strain composition, the variability in vaccine efficacy hampers our ability to make long-term predictions.
Introduction

1
As a significant contributor to global morbidity and mortality, seasonal influenza is an ongoing 2 public health concern. Worldwide, these annual epidemics are estimated to result in about three 3 
to five million cases of severe illness, and about 290,000 to 650,000 respiratory deaths [1] . In 4 England, seasonal influenza inflicts a stark burden on the health system during winter periods, 5 being linked with approximately 10% of all respiratory hospital admissions and deaths [2] . 6 Influenza vaccination can offer some protection against seasonal influenza infection for the in-7 dividual, while contributing to reduced risk of ongoing transmission via establishment of herd 8 immunity [3, 4] . Influenza vaccines are designed to protect against three or four different in-9 fluenza viruses; two influenza A viruses (an A(H1N1)pdm09 subtype and A(H3N2) subtype) and 10 either one or two influenza B viruses (covering one or both of the B/Yamagata and B/Victoria 11 lineages). In 2013, 40% of countries worldwide recommended influenza vaccination in their 12 national immunisation programmes, although vaccine uptake varies [5] [6] [7] . 13 For England (and elsewhere), the need to deploy updated vaccines on an annual basis means 14 influenza vaccination programmes are costly. Yet, predictions of vaccine impact are difficult due 15 to stochasticity in the annual strain composition, the potential misalignment between vaccine 16 and the dominant co-circulating strains and the interaction between multiple seasons. Analysis 17 informing the efficient use of limited resources is therefore vital, with the use of quality-assured 18 analytical models advocated [8] . 19 The previous ten years have seen the fruitful development of influenza transmission models tied 20 to available real-word and experimental data sources [9] [10] [11] [12] [13] [14] [15] . Furthermore, combining parame- 21 terised transmission models with health economic evaluations permits assessments of changes 22 to vaccination programmes, providing evidence to inform vaccine policy decisions [16, 17] . An 23 eminent study by Baguelin et al. [12] connected virological data from England and Wales to 24 a deterministic epidemiological model within a Bayesian inference framework. The transmis- 25 sion model was subsequently interfaced with a health economic analysis model, leading to the 26 recommendation of introducing a paediatric seasonal influenza vaccination programme in the 27 United Kingdom [17] . Subsequent studies have analysed the effect of mass paediatric influenza 28 vaccination on existing influenza vaccination programmes in England and Wales [18] , evaluated 29 cost-effectiveness of quadrivalent vaccines versus trivalent vaccines [19] , and cost effectiveness of 30 high-dose and adjuvanted vaccine options in the elderly [20] . 31 Prior modelling studies have typically treated each season and each strain circulating within that 32 season independently. Though there are instances of model conceptualisations incorporating 33 waning immunity for natural infection and vaccination, these assumed one generic influenza 34 virus [13] , or treated one or both of the influenza A and influenza B types as sole entities 35 rather than explicitly distinguishing between the two common influenza A subtypes and two co- 36 circulating influenza B lineages [9, 11, 16] . Here, we present a multi-strain, non-age structured, 37 susceptible-latent-infected-recovered (SEIR) type transmission model for influenza incorporating 38 a mechanism to link prior season epidemiological outcomes to immunity at the beginning of the 39 following season. Incorporation of a mechanism for the building and propagation of immunity 40 facilitates investigation of the impact of exposure in the previous influenza season, through 41 natural infection or vaccination, on the disease transmission dynamics and overall disease burden 42 in subsequent years. Accordingly, we sought insights to aid understanding of the longer-term 43 dynamics of the influenza virus and its interaction with immunity at the population level. 44 In this study, we examine the contribution of the differing sources of immunity propagation 45 between years on seasonal influenza transmission dynamics. To this end, we amalgamate mul- 46 tiple sources of epidemiological and vaccine data for England covering the last decade, and fit 47 model outcomes to the available longitudinal data of seasonal rates of general practice (GP) 48 consultations for influenza-like-illness (ILI), scaled by virological surveillance information. We 49 demonstrate that natural infection plays a more prominent role in propagation of immunity to 50 the next influenza season compared to residual vaccine immunity. We conclude by inspecting for- 51 ward projections under disparate vaccine efficacy assumptions to determine long-term patterns 52 of seasonal influenza infection. 53 
Methods
54
Historical data 55 Throughout, we define a complete epidemiological influenza season to run from week 36 to week 56 35 of the subsequent calendar year. We chose week 36 (which typically corresponds to the first 57 full week in September) as the start week to match the start of the epidemic with the reopening 58 of schools. 59 
Consultations in General Practices
60
Since January 1967, the Royal College of General Practitioners (RCGP) Research and Surveil- 61 lance Centre (RSC) has monitored the activity of acute respiratory infections in GPs. The 62 Weekly Return reports the number of persons in the monitored RCGP RSC network practices 63 registered population consulting for ILI (a medical diagnosis of possible influenza with a set of 64 common symptoms, cough and measured or reported fever ≥ 38°C, with onset within the last 65 10 days [21] ). 66 Importantly, the dataset is nationally representative both demographically and spatially; the 67 demographics of the sample population closely resembling the country as a whole, with the 68 RCGP RSC network of practices spread across England in order to reflect the distribution of the 69 population. In May 2017, the RCGP RSC network included 1,835,211 patients (approximately 70 3.3% of the total population in England) from 174 practices [22] .
71
For the influenza seasons 2009/2010 until 2017/2018 inclusive, RCGP RSC provided weekly, 72 age-stratified records containing the size of the monitored RCGP RSC population, the number 73 of individuals in the monitored population consulting for ILI, and ILI rates per 100,000. These 74 data were aggregated across ages to produce weekly ILI rates per 100,000 for the entire sample 75 population. We then summed the weekly ILI rates (weeks 36 through to week 35 in the follow-76 ing calendar year) to produce season-by-season ILI rates per 100,000. Expanded information 77 pertaining to the data extraction is provided in Section 1.1 of the Supporting Information.
78
Respiratory Virus RCGP RSC Surveillance
79
To complement syndromic surveillance, a subset of GPs in the RCGP RSC submit respiratory 80 samples from patients presenting in primary care with an ILI. These respiratory samples undergo 81 virological testing to ascertain presence or absence of influenza viruses. Given not all patients 82 reporting ILI are infected with an influenza virus, these virological sample positivity data yield 83 the fraction of ILI reported primary care consultations that were attributable to influenza.
for ILI by the virological surveillance information we garnered an overall estimate of ILI GP 89 consultations attributable to influenza.
90
Circulating strain composition 91 We derived seasonal rates of primary care consultations attributable to each of the two influenza 92 A subtypes (A(H1N1)pdm09 and A(H3N2)) and the two influenza B lineages (B/Victoria and 93 B/Yamagata) per 100,000 population. We computed the circulating strain distribution in each 94 influenza season using publicly available data from FluNet [26] , a global web-based tool for 95 influenza virological surveillance, using data for the United Kingdom (additional details are 96 provided in Section 1.3 of the Supporting Information).
97
ILI GP consultations attributable to influenza
98
We applied the circulating strain composition quantities to the overall estimate of ILI GP consultations attributable to influenza, disaggregating the estimate for all influenza strains of interest into strain-specific quantities:
GP consultation rate for strain m in season y = C m,y = GP ILI consultation rate × . . .
Proportion of ILI samples influenza positive × . . . (1)
Proportion of influenza viruses in circulation of strain type m These computations resulted in seasonal rates of GP consultations attributable for the two in-99 fluenza A subtypes and two influenza B lineages per 100,000 population ( Fig. 1(a) ). Uncertainty 100 distributions for these values were obtained via bootstrapping given the sample sizes for the three 101 components. For the 2009/10 influenza season, we acquired vaccine uptake profiles from survey results on 104 H1N1 vaccine uptake amongst patient groups in primary care [27] . For the 2010/11 influenza 105 season onward we collated vaccine uptake information from PHE official statistics [24, 25] .
(a)
106
We took age adjusted vaccine efficacy estimates for each historical influenza season (2009/2010-107 2017/2018 inclusive) from publications detailing end-of-season seasonal influenza vaccine effec-108 tiveness in the United Kingdom [28] [29] [30] [31] [32] [33] [34] . In seasons where equivalent publications were not 109 available, we used mid-season or provisional end-of-season age adjusted vaccine efficacy esti-110 mates from PHE reports [35, 36] .
111
There has been substantial variation in vaccine efficacy between seasons and also within seasons 112 across strains, with estimates spanning 23-92% (Table 1) we used the pandemic vaccine (rather than the seasonal influenza vaccine efficacy) to inform 117 efficacy against A(H1N1)pdm09, with the effectiveness against all other strain types set to 118 zero [28] .
119
The empirical data did not provide individual vaccine efficacy estimates for each influenza A 120 subtype and influenza B lineage (Table S1) . We therefore used a set of simplifying assumptions 121 to produce the strain-specific, vaccine efficacy point estimates used within our study (Table 1) . 122 The time-varying vaccine uptake data, together with the season-specific information on vaccine 123 efficacy, act as forcing for the within-season epidemiological model (details are described in 124 Sections 1.4-1.5 of the Supporting Information).
125
Modelling overview
126
Our motivation was to study the role of immunity propagation in seasonal influenza transmission 127 dynamics by developing and applying a modelling framework incorporating multiple mechanisms 128 linking prior season infection (or vaccination) to immunity in subsequent seasons.
129
Influenza transmission dynamics are highly complex, with many temporal and structural het-130 erogeneities that will influence the precise pattern of recorded infection. Consequently, our aim 131 was to capture the general trends in the data, such as the pattern of high and low infection 132 levels, rather than the precise values for each influenza season. We, therefore, deliberately chose 133 a parsimonious mechanistic modelling framework, without age-structure, to highlight the impact 134 of immunity propagation.
135
Following the visualisation convention used in [12] , we display a directed acyclic graph repre-136 senting the model structure and incorporation of the data streams (Fig. 2) . The model takes 137 the form of a deterministic continuous-time set of ordinary differential equations (ODEs), which 138 determines the within-season epidemiological dynamics, and a discrete-time map, informing the 139 propagation of immunity from one season to the next. [28] . We therefore used the pandemic vaccine to inform efficacy against A(H1N1)pdm09, with the effectiveness against all other types set to zero. †: Mid-season estimate of seasonal influenza vaccine effectiveness from [35] . that individuals may only be infected by one strain of influenza virus per season, analogous to 146 natural infection eliciting short-term cross immunity to all other strain types [37] .
147
Next, we summarise, in turn, the vaccination, immunity propagation, epidemiological and ob-148 servation model components.
149
Vaccination model
150
Epidemiological states were compartmentalised based on present season vaccine status (indexed 151 by N for non-vaccinated or V for vaccinated). We obtained weekly time-varying vaccine uptake 152 rates, ν, at the population level by computing a weighted average of the individual age group 153 uptake values, thereby accounting for the population distribution in each given influenza season. 154 We assumed the rate of vaccination ν to be constant over each weekly period. Vaccine efficacy 155 depended upon the extent to which the strains in the vaccine matched the circulating strain in 156 that influenza season (Table 1) . receiving the 'leaky' vaccine were equally as infectious as those who did not [39] ); (iii) residual strain-specific protection carried over 177 from the prior season influenza vaccine, denoted c m . We mandated that 0 < a,b,c m < 1. We 178 let f (h, m) denote, for those in exposure history group h, the susceptibility to strain m. The 179 collection of ten exposure history groupings and associated strain-specific susceptibilities were 180 7 consolidated into a single susceptibility array (Fig. 2, process B; Fig. 3 ).
181
We assumed the immunity propagation due to vaccination in the previous season (c m ) to be 182 associated to the strain-specific vaccine efficacy in the previous season (α y−1 m ). In particular, we 183 introduce a linear scaling factor ξ ∈ (0, 1), which reduces the level of vaccine derived immunity 184 between seasons: c 
185
On a related note, we applied a further assumption in order to parameterise susceptibility values 186 amongst exposure groups capturing those both vaccinated and naturally infected in the prior 187 season (Fig. 3: rows 7-10 ). For this collection of exposure histories, susceptibility to a subset of 188 strains may conceivably be collectively modified via natural infection and vaccination immunity 189 propagation pathways. In these instances, we treated the immunity propagation mechanisms 190 independently, with the modified susceptibility set by the dominant immunity propagation entity 191 (i.e. min(a, c m ), min(b, c m )). In other words, we took a pessimistic stance by assuming no 192 boosting of the immunity propagation response as a result of dual influenza virus exposure 193 (from both natural infection and vaccination).
194
All three propagation parameters (a, b, ξ) were inferred from epidemiological data. A mathe-195 matical description of the immunity mapping between seasons is given in Section 2.2 of the 196 Supporting Information.
197
In light of there being uncertainty around the precise time scale for which immunity to seasonal 198 influenza viruses may be retained, with individual-and population-level models having estimated 199 infection acquired immunity to wane over a timescale of two to ten years [40] [41] [42] ), we also 200 considered an extended variant of the immunity propagation model component.
201
In the model extension, we fit an additional parameter (δ) representing the proportion of those 202 who began the influenza season in an exposure history group linked to natural infection ( Figure S20 ). For clarity, we did not introduce a mechanism to confer 210 vaccine-induced immunity beyond one influenza season (i.e. vaccine-induced immunity could be 211 retained for, at most, a single additional influenza season).
212
With the more complex immunity structure, we did not gain noticeable improvements in cor-213 respondence of model outputs with the data (relative to fits with a model using the simpler 214 immunity propagation setup). Therefore, we do not discuss any further here the alternative 215 immunity propagation structure, instead giving a complete description of the extended model 216 and associated outcomes in Section 5 of the Supporting Information.
217
Epidemiological model
218
The within-season transmission dynamics were performed by an ODE epidemiological model 219 based on SEIR-type dynamics. At the start of each season we passed into the epidemiological 220 model the vaccination attributes (uptake and efficacy), immunity considerations, virus trans-221 mission rates and the initial proportion of the population infectious per strain. These collection 222 of epidemiological inputs act as forcing parameters (Fig. 2 , process C). The interaction between exposure history h and susceptibility to strain m in the current season, f (h, m), was classified into ten distinct groups: One group for the naive (uninfected and not vaccinated, row 1); one group per strain, infected but not vaccinated (rows 2-5); one group for those vaccinated and experiencing no natural infection (row 6); one group per strain for being infected and vaccinated (rows 7-10). We let a denote modified susceptibility to strain m given infection by a strain m type virus the previous season (dark green shading), b modified susceptibility due to cross-reactivity between type B influenza lineages (dark blue shading), and c m the change in susceptibility to strain m given vaccination in the previous season (gold shading). Unmodified susceptibilities retained a value of 1 (red shading). We enforced 0 < a,b,c m < 1.
The epidemiological model is a deterministic, non-age, multi-strain structured compartmental 224 based model capturing demography, influenza infection status (with susceptible-latent-infected-225 recovered, SEIR, dynamics) and vaccine uptake. For influenza, it is commonplace to also consider 226 a risk-stratified population, divided into individuals at low or high risk of complications associ-227 ated with influenza. However, it is health outcomes, rather than epidemiological processes, that 228 are contingent upon risk status [12] and therefore this additional structure can be ignored for 229 the purposes of this model. We assumed disease transmission to be frequency-dependent, such 230 that fundamental quantities (like the basic reproductive ratio, R 0 ) are unaffected by changes to 231 population size.
232
We assumed exponentially-distributed latent and infectious periods (arising from rates of latency 233 loss and recovery, respectively, being constant). Loss of latency rates γ 1,m were strain-dependent. 234 From Lessler et al. [43] , we chose rates corresponding to average latent periods of 1.4 days and 235 0.6 days for influenza A and influenza B associated strains respectively. Following Cauchemez 236 et al. [44] , we set the rate of loss of infectiousness γ 2 = 1/3.8, corresponding to an average 237 infectious period of 3.8 days, independent of strain.
238
We set the mortality rate based upon a gender-averaged life expectancy for England, approxi-239 mated from male and female specific statistics from Office for National Statistics data [45] (see 240  Table 2 ).
241
The ODE equations of the SEIR epidemiological model are given in Section 2.3 of the Supporting 242 Information. The strain specific force of infection, λ m , satisfies where β m is the transmission rate for strain m, implicitly comprising the contact rate and the 244 transmissibility of the virus (the probability that a contact between an infectious person and a 245 susceptible person leads to transmission), and the superscript X ∈ {N, V } denotes vaccination 246 status (indexed by N for non-vaccinated, V for vaccinated).
247
For use in our observation model, we tracked the incidence Z m (y) of new strain m influenza 248 infections in season y as a rate per 100,000 population:
Observation model
250
As discussed above, individuals consulting a GP for ILI do not necessarily directly correspond 251 with individuals infected with one of the circulating influenza strains. To address this dis-252 crepancy, the final segment of the mathematical model linked the GP consultation data with 253 the number of infections due to circulating influenza viruses in the population (Fig. 2 , process 254 D).
255
Our interest resided in the number of ascertainable cases, where we assumed that each individual 256 infected by the strain of influenza under consideration had a probability of being ascertainable, 257 i.e. going to the GP, being recorded as having ILI, and having a detectable influenza viral load. 258 We assumed the ascertainment probability was season-specific (but strain agnostic) to account 259 for a range of influences such as climate or co-circulating infections. We obtained model estimates 260 of the proportion of individuals experiencing cases of ascertainable influenza (of strain type m) 261 in season y through scaling the incidence Z m (y) by the ascertainment probability in influenza 262 season y, y . Consequently, the ascertainable influenza cases in season y, Z + m (y), obeys:
The parameter y is inferred by comparing the total predicted incidence in a given year to the 264 calculated GP consultation rate (Eq. (1)).
265
Parameter inference
266
To realise a model capable of generating influenza-attributed ILI GP consultations estimates 267 that resemble the empirical data (Eq. (1)), we sought to fit the following collection of model 268 parameters ( Table 2) : transmissibility of each influenza virus strain (β m ), modified susceptibility 269 to strain m given infection by a strain m type virus the previous season (a), carry over cross-270 reactivity protection between influenza B lineages (b), residual protection carried over from 271 the prior season influenza vaccine (ξ), and an ascertainment probability per influenza season 272 ( y ). One may notice the ascertainment probabilities were the sole group of parameters that 273 could vary between influenza seasons, and we acknowledge that one may feasibly apply temporal 274 (influenza season) dependencies to the transmission rates and immunity propagation parameters. 275 Nevertheless, despite the the integration of additional parameters potentially improving the fit 276 to the data, we would be running the risk of the model containing more parameters than can 277 be justified by the data (overfitting). Instead, our intention was to extract a signal across the 278 considered time frame, if present, identifying the most prominent transmission rates (comparing 279 across the four influenza viruses) and immunity propagation mechanisms.
280
For inferring posterior parameter distributions, we employed an adaptive-population Monte 281 Carlo approximate Bayesian computation (ABC) algorithm [46] combined with a local per-282 turbation kernel (multivariate normal kernel with optimal local covariance matrix) [47] . Prior 283 distributions were uniform for all parameters (Table 2) .
284
Simulations began in the 2009/2010 influenza season and ran for a specified number of seasons 285 with one parameter set. For the 2009/2010 influenza season, only the A(H1N1)pdm09 strain was 286 present in our simulation (in accordance with the strain composition data where proportions of 287 samples for the remaining three strains were very low, Fig. 1(a) ), with the initial proportion of 288 the population infected being 1 × 10 −5 (one per 100,000). In all subsequent influenza seasons, 289 with all four influenza virus strains being present, the initial proportion of the population infected 290 by each strain was 2.5 × 10 −6 . We fit to the 2012/13 season onward, which omitted the influenza 291 seasons (2009/10 and 2011/12) that had no influenza B lineage typing data (Fig. 1 ). This selected 292 time frame contained a regime in which the dominant circulating influenza A subtype generally 293 switched annually between H1N1(2009) and H3N2, while for type B influenza the Yamagata 294 lineage incidence typically exceeded Victoria lineage incidence.
295
The summary statistics for our ABC procedure were comprised of two parts. The first component 296 was a within-season temporal profile check; the peak in influenza infection (combining those in 297 latent and infectious states) could not occur after February in any season. The second component 298 defined the metric to measure the correspondence of the model predicted influenza-attributed 299 ILI GP consultations versus the observed data. We worked with a metric akin to Poisson 300 deviance. Compared to a sum of squared residuals error metric, a measure akin to Poisson 301 deviance penalises with greater severity poor fits to data points of small magnitude. Accounting 302 for season y and strain stratification m, we defined our deviance measure to be
with C m,y the observed value for strain m in season y, and M m,y the model estimate for strain 304 m in season y.
305
We amassed 10,000 particles representing a sample from the posterior distribution (see Section 306 3 of the Supporting Information for expanded details on the parameter estimation methodol-307 ogy). 
Results
329
330
We invoked the adaptive-population Monte Carlo ABC algorithm, accumulating 10,000 param-331 eter sets (representing a sample from the posterior distribution) to determine credible values of 332 the model parameters (Table 3) . Samples were obtained after completion of 600 generations of 333 the adaptive-population Monte Carlo ABC scheme, at which point the generation-by-generation 334 tolerance level updates were minor (Fig. 4(a) ). Accordingly, additional simulations would only 335 marginally change the posterior distributions. The model parameters were well defined, with 336 Gaussian-shaped histograms (Fig. 4(b) ). All parameter sets adhered to the mandatory temporal 337 criteria of peak infection in each influenza season occurring prior to March ( Figure S5 ). Inspecting the attained posterior distributions for virus transmissibility, estimates for the two in-339 fluenza A subtypes are similar; both are larger than the corresponding estimates for the two type 340 B lineages. However, the B/Yamagata transmissibility estimates exceeded those for B/Victoria, 341 although the values are relatively close.
338
342
Amongst the three exposure history parameters (a, b, ξ), the parameter having a notable impact 343 on the transmission dynamics was the modification to susceptibility due to natural infection in 344 the previous influenza season (a). If infected by a given strain last season, the inferred weighted 345 median estimate of 0.7883 corresponds to an approximate 21% reduction in susceptibility to the 346 current season variant of that strain type. Strikingly, there was little carry over of prior season 347 vaccine efficacy (ξ), with the majority of the posterior distribution massed near 0. Similarly, 348 being previously infected by one of the type B influenza virus conferred little immunity against 349 the remaining type B lineage virus in the next season. We verified model robustness by performing parameter fits using two subsets of the histor-355 ical influenza season data, spanning the time periods 2012/13-2015/16 and 2012/13-2016/17 356 respectively. Fitting to these differing influenza season ranges, outcomes generally exhibited 357 qualitative consistency; in particular, amongst the three mechanisms for immunity propaga-358 tion, current season susceptibility was modulated greatest by natural infection in the previous 359 influenza season. The only notable quantitative differences when fitting to the two shortened 360 13 time frames (compared to the distributions inferred when fitting to the complete time period) 361 were elevated transmissibility levels (β), counteracted by an enlarged effect of prior infection 362 (a) and vaccination propagation (ξ); further details are given in Section 4.2 of the Supporting 363 Information.
364
In addition, we assessed the parameter identifiability competency of our ABC fitting scheme 365 via generation of synthetic data from known parameters. Employing our inference scheme to 366 fit the model to the synthetic data, we ably recovered the parameter values from which the 367 synthetic data had been generated, giving extra confidence to our results (see Section 4.3 of the 368 Supporting Information). 
Evaluating model fit
370
To assess the goodness-of-fit between our model and the available data, we performed 1,000 371 independent simulations using parameter sets drawn from the ABC inference procedure. There-372 fore, although the model is deterministic, we generated variability in epidemic composition due 373 to the posterior distribution for the underlying parameters. The incidence of each of the four 374 influenza types over each season was converted to attributed GP consultations (per 100,000), 375 with both incidence and GP consultation outputs compared to the data (Fig. 5) . We generally 376 obtained a reasonable fit to the data, both in terms of the severity of infection each year (as 377 controlled by the ascertainment y ) but also in terms of type and subtype composition (which 378 is largely driven by epidemiological dynamics and propagation of immunity).
379
Considering type A influenza, we clearly captured the alternating pattern of dominance by 380 A(H3N2) and A(H1N1)pdm09 subtypes for the years 2012/13 to 2016/17; but more importantly 381 the model was able to predict the unexpected result that A(H3N2) dominated in both 2016/17 382 and again in 2017/18. For influenza B, we obtained modest agreement for the overall magnitude 383 of GP consultations as a result of type B, but this was not always in complete agreement with 384 the subtype composition ( Fig. 5(a) ).
385
A more detailed comparison of predicted and observed subtypes in each season allowed us to 386 analyse discrepancies in more detail (Fig. 6 ). The model predictions are shown with a violin plot 387 to capture the variability in the distribution due to parameter uncertainty; while the observed 388 data has confidence intervals (calculated from bootstrapping) due to the finite sample sizes. Stratified by influenza season, we present back-to-back stacked bars per simulation replicate, with 1,000 replicates performed, each using a distinct parameter set representing a sample from the posterior distribution. Each influenza season is topped out by a thicker stacked horizontal bar plot, corresponding to the strain-stratified point estimates for the empirical data. (a) Posterior predictive distributions for circulating influenza virus subtype/lineage composition. (b) Posterior predictive distributions for influenza positive GP consultations per 100,000 population. In both panels, the left side depicts data pertaining to type A influenza viruses (red shading denoting the A(H1N1)pdm09 subtype, orange shading the A(H3N2) subtype). In an equivalent manner, the right side stacked horizontal bars present similar data for type B influenza (cyan shading denoting the B/Victoria lineage, dark blue shading the B/Yamagata lineage). We see a reasonable qualitative model fit to the data, especially for the two influenza A subtypes. 
Forward simulations
399
Using the parameter set from the inference scheme returning the closest correspondence with 400 the data (lowest DEV value, Eq. (5)), we explored potential strain dynamics up to the 2029/30 401 influenza season under contrasting vaccine efficacy settings (Fig. 7) .
402
When maintaining 'expected' vaccine efficacy (A(H1N1)pdm09: 55.25%; A(H3N2): 30.45% 403 B/Victoria: 55.90%; B/Yamagata: 52.60%) across all future seasons ( Fig. 7(a) , single bars), 404 we witness minor variability in predicted influenza incidence for both influenza types. leading to broadly higher levels of influenza A and lower levels of influenza B (Fig. 7(a) ).
420
Comparing subtype distributions when vaccine efficacies were either sampled from historical 421 estimates or fixed at 'expected' values, we found that under randomly sampled vaccine effi-422 cacies incidence of B/Yamagata tended to exceed B/Victoria in each season (holding in more 423 than 70% of simulations, Figure S18 ). However, we obtained greater levels of variation for the 424 influenza A subtypes. In an 'expected' vaccine efficacy setting (single bars), less than half of to-425 tal influenza A cases in any season were attributed to the A(H1N1)pdm09 subtype (rather than 426 A(H3N2)), whereas under variable vaccine efficacies (distributed bars) A(H1N1)pdm09 incidence 427 was greater than A(H3N2) incidence in 30-50% of all simulations ( Figure S18 ). Furthermore, in 428 each future influenza season the majority of simulations (∼60-75%) performed with seasonally 429 variable vaccine efficacies resulted in overall incidence rates exceeding the equivalent seasonal 430 incidence estimates generated under 'expected' vaccine efficacy conditions.
431
The impact of vaccine efficay on projected incidence is further exemplified by the stark contrast 432 in predictions when comparing the pessimistic scenario (A (H1N1) For the pessimistic vaccine efficacy scenario (compared to the other fixed vaccine efficacy scenar-439 ios) we also observe the strongest re-emergence of the alternating behaviour between dominant 440 influenza A subtypes ( Fig. 7(b) ).
441
Maintaining a high vaccine efficacy, both influenza types had consistent incidence estimates. 442 Whilst combined influenza B incidence was low, ranging approximately between 600-1700 cases 443 per 100,000 each season, seasonal influenza A incidence frequently reached 25,000-30,000 cases 444 per 100,000. Although we, once more, predict periodic behaviour for the portion of influenza 445 A viruses in circulation ascribed to the subtypes A(H1N1)pdm09 and A(H3N2), under these 446 optimistic vaccine efficacy conditions it was influenza seasons ending in odd numbered years 447 having a relatively even split between the two subtypes; whereas for influenza seasons ending in 448 even numbered years the A(H3N2) subtype dominated A(H1N1)pdm09 (Fig. 7(c) ).
449
(a) (b) (c) 
459
With a view to minimising the number of independent parameters, we fit a parsimonious mecha-460 nistic model to seasonal-level data on strain competition. In spite of the multi-strain complexity 461 and time scale of the study period (six influenza seasons), predictions from the model attain a 462 strong qualitative resemblance (in terms of strain composition and overall quantity of GP con-463 sultations) to the empirical subtype data from England. We attribute much of the discrepancies 464 to the homogeneous way in which we have treated immunity propagation, as in practise this is 465 driven by complex patterns of waning and cross immunity as well as somewhat irregular genetic 466 drift.
467
Inferred transmissibility of type A influenza strains exceeding those of type B, which reflects 468 type A being the predominant class of influenza virus in circulation over the studied time pe-469 riod [26] . Moreover, concentrating on the parameters relevant to immunity propagation, we 470 uncover evidence against vaccination stimulating similar long-term immunity responses as for 471 natural infection. These conclusions corroborate previous immunological studies showing that 472 infection with influenza virus can induce broader and longer-lasting protection than vaccina-473 tion [37, 48, 49] , and authenticate prior work signalling that vaccine-mediated immunity rapidly 474 wanes [50] . There are also indications that prior natural infection boosts vaccine responses 475 against antigenically drifted strains, whereas prior vaccination does not [51] . The clinically ob-476 served impact of prior infection for enhancing vaccine efficacy was long-lasting, which may be 477 used to instruct further model refinements.
478
In the case of finding minimal support for carry over cross-reactivity protection between in-479 fluenza B lineages (parameter b), we have reported the best parameter fits under the modelling 480 assumptions made. Considered collectively, the inferred parameter fits signify that, at the pop-481 ulation level, a combination of transmissibility rates, season-specific ascertainment probabilities 482 and modifications to susceptibility by lineage-specific immunity propagation (parameter a) and 483 within-season vaccination are sufficient to obtain the closest correspondence to the data under 484 the modelling assumptions, without requiring a prominent amount of influenza B cross-reactive 485 immunity propagation. In other words, if there were presence of propagation of protection be-486 tween influenza B lineages, it is dwarfed by other processes within the biological system. The lack 487 of propagation of cross-reactivity protection between influenza B lineages may be unforeseen, 488 as it has been documented that there is potential for viral interference between the influenza 489 B virus lineages; infection with one influenza B virus lineage may be beneficial in protecting 490 against subsequent infection with either influenza B virus lineage [39] . However, these experi-491 ments (using a ferret model of human influenza) had a short separation between primary and 492 challenge virus infections (at most 28 days), whereas our timescale of interest is of the order 493 of six months (spanning between peak infection in one influenza season to the initiation of the 494 seasonal epidemic in the next).
495
The extent of immunity propagation stemming from earlier influenza infection and vaccination 496 occurrences may conceivably be quantified through serological surveys, potentially the most 497 direct and informative technique available to infer the dynamics of a population's susceptibility 498 and level of immunity [52] . There is scope to implement concepts monitoring changes in the 499 immune response to infections in a rapid and cost-effective manner, by using existing primary 500 care sentinel networks [53] . In this fashion, in England an age-stratified pilot serology study 501 was recently initiated utilising the RCGP RSC to collect serological specimens and associated 502 patient data to measure seropositivity and seroincidence due to seasonal influenza [54] . These 503 progressive developments make usage of serological data to validate our study findings a realistic 504 prospect.
505
Furthermore, though there have been studies carried out to quantify the strength of vaccine 506 induced herd immunity for seasonal influenza [3, 4] , the role of immunity originating from non-507 immunising exposure to influenza viruses in inducing herd immunity is unexplored. An upsurge 508 in serology data would promote such assessments.
509
Ascertainment probabilities are key for linking population levels of influenza infection to GP-510 reported incidence. For greater parsimony we have assumed that ascertainment is independent 511 of subtype, which could be an over-simplification in some years; but allowing ascertainment to 512 depend on both season and subtype would over-fit the model. Across all considered influenza 513 seasons, we found ascertainment probabilities were of a similar order (and concurred with the 514 magnitudes of inferred ascertainment probabilities in [12] ), with the greatest values obtained 515 for the 2017/18 influenza season. The 2017/18 season saw moderate to high levels of influenza 516 activity observed in the UK [24] , exacerbated by a mismatch of the A(H3N2) component of the 517 available vaccine towards the A(H3N2) strain in circulation [36] . The effects that consequential 518 increased media coverage of an outbreak have on transmission dynamics can be complex [55] , 519 with the perception of the disease conceivably changing among the population [56] . Chiefly in 520 this instance, for those infected and symptomatic the propensity to consult a GP may have been 521 abnormally raised, which would result in an increased ascertainment probability relative to prior 522 influenza seasons.
523
While historic immunity is predicted to play an important role in determining annual strain 524 composition (leading to subtype patterns between seasons), our projections of the dynamics 525 forward in time exemplify how variability in vaccine efficacy hampers our ability to make long-526 term predictions. Spanning our pessimistic to optimistic vaccine efficacy scenarios, we generally 527 attained a model predicted incidence (per influenza season) of 30-50%. With volunteer challenge 528 studies indicating that the majority of those infected by influenza are asymptomatic [57] , plus 529 only around 10% of those with ILI thought to consult a GP [58, 59] , our model predicted influenza 530 incidence pairs satisfactorily with previous influenza burden estimates covering England [60] . 531 Additionally, influenza burden estimates in the USA (provided by the CDC) covering the 2017/18 532 and 2018/19 influenza seasons ascribe more than 48.8 million and 37.4-42.9 million influenza 533 associated illnesses respectively, which is in the realms of 10-15% of the national population 534 suffering symptomatic infection [61, 62] .
535
Consistently high vaccine efficacies would aid forecasting efforts, providing additional benefits 536 beyond the reduction in disease offered by new vaccines with improved clinical efficacy and 537 effectiveness [63] . Most importantly, with annual emergence of drift variants of influenza viruses, 538 cross-protective vaccines are needed to heighten protective effectiveness [64] .
539
The development of the influenza transmission model presented here was built upon a collection 540 of simplifying assumptions. A limitation of the model is fixing the influence of prior expo-541 sure history to a single season. Studies of repeated vaccination across multiple seasons suggest 542 that vaccine effectiveness may be influenced by more than one prior season [65] . In an United 543 Kingdom-centric analysis, Pebody et al. [34] scrutinised the possible effect of prior season vacci-544 nation on 2016/17 influenza season vaccine effectiveness; while there was no evidence that prior 545 season vaccination significantly reduced the effectiveness of influenza vaccine during the current 546 season in adults, it was deemed to increase effectiveness in children. Extending exposure history 547 and susceptibility interaction functionality to encompass immunity propagation dependencies 548 beyond one prior influenza season would assist efforts evaluating the potential effect of repeat 549 influenza vaccinations in the presence of vaccine interference [66] .
550
Second, on the basis of model parsimony, within the immunity propagation model component 551 we limited the number of mechanisms linking prior influenza season exposure history to suscep-552 tibility in the subsequent influenza season. Though we did include a parameter corresponding to 553 immunity proliferating across influenza B lineages between seasons, we did not include influenza 554 A heterosubtypic immunity amongst the immunity propagation mechanisms. Recent work has 555 found H1 and H3 influenza infection in humans induces neuraminidase-reactive antibodies dis-556 playing broad binding activity spanning the entire history of influenza A virus circulation (in 557 humans) [37] ; these developments motivate continued work and data acquisition to elicit the 558 timespan over which cross-reactive antibodies (arising from natural influenza infection) may sig-559 nificantly reduce susceptibility to unrelated influenza A subtypes and influenza B lineages.
560
Third, we assumed the mechanism underpinning propagation of immunity from influenza vac-561 cination in the previous season behaved linearly. We recognise a linear dependency is a strong 562 generalisation. Given the vaccine-induced protection to an influenza virus strongly depends on 563 the level of mismatch of the strain contained in the vaccine and the circulating strain, a vaccine 564 that is very protective in the current influenza season might be ineffective the following year 565 due to the influenza virus undergoing antigenic mutation. Thus, alternative non-linear formu-566 lations for the vaccine-derived immunity propagation process warrant consideration, if there is 567 sufficiently detailed data to underpin the models.
568
Relatedly, to parameterise the amended strain-specific susceptibility values within exposure his-569 tory groups encapsulating those both experiencing a natural infection event and undergoing 570 vaccination in the prior influenza season, we assumed no interaction between residual vaccine 571 and natural infection immunity (we simply enforced the dominating process). Other formula-572 tions governing the interaction between residual vaccine and natural infection immunity may be 573 scrutinised, conditional on the emergence of relevant data to parameterise the process.
574
Fourth, for simplicity we assumed each season was initialised with a low level of all subtypes; in 575 practise the subtypes seeding each epidemic will be contingent on the dynamics in the rest of the 576 world. Finally, we assumed the value of the ascertainment probability to be constant over the 577 course of the influenza season. The underlying assumption is that the quantities contributing 578 towards ascertainment remain stable over time. Yet, in reality there are contributory factors 579 that are likely to vary during the course of each seasonal outbreak; for example, the propensity 580 to consult with a GP if inflicted with symptomatic illness.
581
We view the dynamic influenza transmission model presented here as a foundation stage for 582 influenza modelling constructs incorporating strain and immunity interactions. Heterogeneity 583 in social contact patterns and the role of age in influenza transmission potential and severity of 584 health outcomes are important considerations, with children identified as the main spreaders of 585 influenza infection [67, 68] and most influenza associated deaths occurring among elderly adults 586 and those with co-morbid conditions that place them at increased risk [2, 69] . As a consequence, 587 next steps should include augmenting population mixing patterns and age-structure into the 588 mathematical framework. In addition, coupling the transmission model together with economic 589 evaluation frameworks will permit cost-effectiveness appraisals of prospective vaccination pro-590 grammes.
591
In summary, through the use of mathematical modelling and statistical inference, our analysis 592 of seasonal influenza transmission dynamics in England quantifies the contribution of distinct 593 immunity propagation mechanisms. We find that susceptibility in the next season to a given 594 influenza strain type is modulated to the greatest extent through natural infection by that strain 595 type in the current season, with residual vaccine immunity having a lesser role and inconsequen-596 tial support for carry over type B cross-reactivity. As such, the approach utilised here offers a 597 preliminary basis for long-term influenza modelling constructs incorporating strain and immunity 598 interactions, although forecasts are strongly influenced by vaccine efficacy. We suggest that the 599 adoption of influenza transmission modelling frameworks with immunity propagation provides 600 a comprehensive manner to assess the impact of seasonal vaccination programmes. Figure S1 
Figure S5
Example time series displaying proportion of population in infected states (latent or infectious). Grey lines represent the simulated infected prevalence time series for 10 retained parameter sets from the inference procedure. With each simulation replicate starting on 1st September, red dashed vertical lines designate the beginning of March in each year. As stipulated by our parameter selection criteria, peak infection occurs prior to the 1st March. 
Figure S14
Posterior predictive influenza positive GP consultation distributions, post-fitting to the empirical data covering the 2012/13-2015/16 influenza seasons (inclusive). We generated the estimated distributions from 1,000 model simulations, each using a distinct parameter set from the retained collection of particles. 
Figure S15
Posterior predictive influenza positive GP consultation distributions, post-fitting to the empirical data covering the 2012/13-2016/17 influenza seasons (inclusive). We generated the estimated distributions from 1,000 model simulations, each using a distinct parameter set from the retained collection of particles. (a) Back-to-back stacked bars per simulation replicate. Each influenza season is topped out by a thicker stacked horizontal bar plot, corresponding to the strain-stratified point estimates for the empirical data. (b) Comparison of model simulated outcomes (shaded violin plots, with filled circles corresponding to the median value across the simulated replicates)versus the observed data (crosses denote the point estimate, with solid bars the range of the bootstrapped empirical data).
Figure S16
Results of the ABC scheme, fitting to synthetic data. (a) Summary metric threshold value upon completion of each generation of the inference scheme. The inset panel displays the latter quarter of generations. (b) Inferred parameter distributions estimated from 10,000 retained samples following completion of 1,000 generations of the inference scheme. Vertical red lines indicate the (non-weighted) median values for the model constants estimated from the inference procedure, and vertical black lines correspond to the true values of the parameters from which the data were generated. We ably recovered the parameter values from which the synthetic data had been generated.
Figure S17
Posterior predictive distributions for influenza positive GP consultations per 100,000 population, using the parameter sets generated when fitting to the synthetic data.
Stratified by influenza season, we present back-to-back stacked bars for 1,000 simulation replicates, each using a distinct parameter set representing a sample from the posterior distribution when fitting our mathematical model to the synthetic data. Each influenza season is topped by a thicker stacked horizontal bar plot, corresponding to the synthetic data values. The left side depicts the cumulative total of ILI GP consultations attributable to type A influenza per 100,000 population (red shading denoting the A(H1N1)pdm09 subtype, orange shading the A(H3N2) subtype). In an equivalent manner, the right side stacked horizontal bars present similar data for type B influenza (cyan shading denoting the B/Victoria lineage, dark blue shading the B/Yamagata lineage). Overall, simulated outcomes from each parameter set had strong agreement with the synthetic data.
Figure S18
Quantification of the projected dominating influenza A subtype and influenza B lineage by influenza season, up to 2029/30. The left half depicts the proportion of simulations in which the major subtype contributor (>50% of cases) to the overall type A influenza incidence was A(H1N1)pdm09 (red bars) or A(H3N2) (orange bars). In an equivalent manner, the right half depicts the proportion of simulations in which the major lineage contributor (>50% of cases) to the overall type B influenza incidence was B/Victoria (cyan bars) or B/Yamagata (dark blue bars). Constructed from simulation runs where vaccine efficacy against each strain were randomly sampled from the empirical distribution (totalling 1,000 replicates). For all forward simulated seasons, vaccine uptake matched that of the 2017/18 influenza season.
Figure S19
Schematic showing the links between the vaccination, immunity propagation, epidemiological and observation model components for the extended model. We adopt the visualisation conventions of [12] , with ellipses indicating variables, and rectangles indicating data. Dotted arrows indicate relationships between prior season epidemiological outcomes and immunity propagation factors. Solid arrows indicate within-season processes. Circled capitalised letters indicate the relationships connecting the variables or data involved. These relationships are: process A, propagation of immunity as a result of exposure to influenza virus in the previous influenza season (through natural infection or vaccination); process B, modulation of current influenza season virus susceptibility; process C, estimation of influenza case load via the SEIR model of transmission; process D, ascertainment of cases through ILI recording at GP.
Figure S20
Mechanism for conferring immunity to influenza across multiple influenza seasons.
At the beginning of a generic influenza season y, those susceptible may be divided into two categories based on exposure history: (i) susceptibles in either the naive exposure history group , with unmodified susceptibility to infection, or in the vaccinated only exposure history group (labelled S); (ii) all those that are susceptible and in an exposure history group involving natural infection (labelledŜ). During the influenza season, those that were initially susceptible may be infected (state I). Of those remaining in stateŜ at the end of season y, a proportion δ are retained in stateŜ at the beginning of season y + 1. The remainder (1 -δ) transition to state S. Note, δ = 0 corresponds to no residual immunity being retained due to natural infection beyond one subsequent influenza season, while δ = 1 coincides with residual immunity being kept in all future seasons until the occurrence of a new infection event.
Figure S21 
Figure S22
Posterior predictive influenza positive GP consultation distributions, post-fitting the extended model to the empirical data covering the 2012/13-2017/18 influenza seasons (inclusive). We generated the estimated distributions from 1,000 model simulations, each using a distinct parameter set from the retained collection of particles. (a) Back-to-back stacked bars per simulation replicate. Each influenza season is topped out by a thicker stacked horizontal bar plot, corresponding to the strain-stratified point estimates for the empirical data.
(b) Comparison of model simulated outcomes (shaded violin plots, with filled circles corresponding to the median value across the simulated replicates) versus the observed data (crosses denote the point estimate, with solid bars the range of the bootstrapped empirical data).
Figure S23
Results of the ABC scheme, fitting the extended model to synthetic data. (a) Summary metric threshold value upon completion of each generation of the inference scheme. The inset panel displays the latter tenth of generations. (b) Inferred parameter distributions estimated from 10,000 retained samples following completion of 1,650 generations of the inference scheme. Vertical red lines indicate the (non-weighted) median values for the model constants estimated from the inference procedure, and vertical black lines correspond to the true values of the parameters from which the data were generated. We ably recovered the parameter values from which the synthetic data had been generated.
Figure S24
Posterior predictive distributions for influenza positive GP consultations per 100,000 population, using the parameter sets generated fitting the extended model to the synthetic data. Stratified by influenza season, we present back-to-back stacked bars for 1,000 simulation replicates, each using a distinct parameter set representing a sample from the posterior distribution when fitting our mathematical model to the synthetic data. Each influenza season is topped by a thicker stacked horizontal bar plot, corresponding to the synthetic data values. The left side depicts the cumulative total of ILI GP consultations attributable to type A influenza per 100,000 population (red shading denoting the A(H1N1)pdm09 subtype, orange shading the A(H3N2) subtype). In an equivalent manner, the right side stacked horizontal bars present similar data for type B influenza (cyan shading denoting the B/Victoria lineage, dark blue shading the B/Yamagata lineage). Overall, simulated outcomes from each parameter set had strong agreement with the synthetic data.
Table S1
Adjusted vaccine effectiveness estimates for influenza by season and strain type. 95% confidence intervals are stated within parentheses. 
Table S3
Values (posterior weighted quantiles) for the transmission, exposure history and ascertainment probability parameters inferred fitting to synthetic data. Numbers 36 inside brackets indicate 95% credible intervals. All values are given to 4 d.p.
Table S4
Overview of parameters in the extended model.
Table S5
Values (posterior weighted quantiles) for the transmission, exposure history and ascertainment probability parameters inferred fitting the extended model to the empirical data. Numbers inside brackets indicate 95% credible intervals. All values are given to 4 d.p.
Table S6
Values (posterior weighted quantiles) for the transmission, exposure history and ascertainment probability parameters inferred fitting the extended model to synthetic data. Numbers inside brackets indicate 95% credible intervals. All values are given to 4 d.p.
